1. ELSI Challenges Associated with Clinical Applications of Exome Sequencing: preliminary results from a Systematic Literature Review Gabrielle Bertier, PhD candidate McGill University, Toulouse III University Translation in healthcare conference - Exploring the impact of emerging technologies University of oxford 23-25 June 2015

2. Outline 1.Introduction A.Context & Study objectives B.Methodology 2.Preliminary findings A.Articles overview B.Technology users identified implementation issues 3.Discussion A.Study limitations B.Future steps

3. 1. Introduction A. Context & Objective PhD project Empirical evidence, implementation of whole exome sequencing in the clinical setting Case studies France/Canada Data trajectory: from raw sequencing data to clinical information

4. 1. Introduction A. Context & Objective Whole Exome Sequencing Protein coding regions of all genes ≈2% genome <5.000 CAD Diverse uses Diagnosis, etiology, predisposition, treatment mendelian disorders, undiagnosed diseases, cancer, intellectual disability

5. Study Objective: ELSI Challenges – implementation, data, results Clinical Applications – result use in patient care Exome Sequencing – strict technological focus Technology Users – Researchers, MDs, clinicians 1. Introduction A. Context & Objective

6. 1. Introduction B. Methodology Search EBSCO, EMBASE, PubMed, Science Direct, Scopus, Web of Science (“exome sequencing” OR “whole-exome sequencing” OR “whole exome sequencing”) AND (“Clinical application” OR “Medical application” OR “Healthcare” OR “Clinical care” OR “Medical care” OR “Clinical practice” OR “Clinical diagnostic” OR “Medical practice”)

7. 1. Introduction B. Methodology Filtering processTotal Total hits2.275 Unique, peer reviewed journal articles1714 Analysed714 (42%) Included47

8. 1. Introduction B. Methodology Impl*User WES Issues Inclusion Criteria

9. 2. Preliminary Findings A. Articles overview

10. 2. Preliminary Findings A. Articles overview

11. 2. Preliminary Findings A. Articles overview Acute Myeloid Leukemia, Adult Screening, Autism Spectrum Disorders, Cilipopathies, Deafness, Heart diseases, Intellectual disability, Mendelian disorders, Ocular diseases

12. Production Clinical indications 6% First/ Second tier test 13% Clinicians buy-in 2% Centralized/Local laboratory sequencing 2% Turnaround time 23% Data storage 36% gene patents, IP 9% Cost/ Reimbursement 70% Quality Control standards 40% Analysis Variants of Unknown Significance (VUS) 69% Need for large scale population databases 15% Interdisciplinary collaborations/Roles in the clinic 23% Reporting Incidental Findings (IF) 71% IF standards 45% Reproductive choices 2% Clinicians education 43% VUS standards 55% Pre/Post test Counselling, Communication 26% Availability of Results Ownership, access, privacy 32% Genetic Discrimination 15% Electronic Health Records 6%

13. Production Clinical indications 6% First/ Second tier test 13% Clinicians buy-in 2% Centralized/Local laboratory sequencing 2% Turnaround time 23% Data storage 36% gene patents, IP 9% Cost/ Reimbursement 70% Quality Control standards 40% Analysis Variants of Unknown Significance (VUS) 69% Need for large scale population databases 15% Interdisciplinary collaborations/Roles in the clinic 23% Reporting Incidental Findings (IF) 71% IF standards 45% Reproductive choices 2% Clinicians education 43% VUS standards 55% Pre/Post test Counselling, Communication 26% Availability of Results Ownership, access, privacy 32% Genetic Discrimination 15% Electronic Health Records 6%

14. Production Clinical indications 6% First/ Second tier test 13% Clinicians buy-in 2% Centralized/Local laboratory sequencing 2% Turnaround time 23% Data storage 36% gene patents, IP 9% Cost/ Reimbursement 70% Quality Control standards 40% Analysis Variants of Unknown Significance (VUS) 69% Need for large scale population databases 15% Interdisciplinary collaborations/Roles in the clinic 23% Reporting Incidental Findings (IF) 71% IF standards 45% Reproductive choices 2% Clinicians education 43% VUS standards 55% Pre/Post test Counselling, Communication 26% Availability of Results Ownership, access, privacy 32% Genetic Discrimination 15% Electronic Health Records 6%

15. 2. Preliminary Findings B. Implementation Issues Implementation underway: technological push Wide range of issues Clear call for Standards

16. 2. Preliminary Findings B. Implementation Issues Who should regulate? Professional societies, disease specific implementation regulation? Hospital policies? (IF, VUS) Regional/national policies (QC?) Others

17. 2. Preliminary Findings B. Implementation Issues JurisdictionSourceRef USAAmerican College of Medical Genetics17 USA Presidential Commission for the Study of Bioethics issues 0 EuropeEuropean society of Human Genetics0 CanadaCanadian college of Medical geneticists0

18. 3. Discussion A. Study limitations Search, filtering and inclusion criteria Preliminary Results (42% results analysed only) Analysis structure and focus

19. 3. Discussion B. Future Steps Second researcher looking through the data Finish data analysis Analysis of current regulatory framework

20. Acknowledgements Professor Yann Joly Professor Bartha Maria Knoppers Martin Hétu Professor Anne Cambon Thomsen